Evaluation of the Ameliorative Potential of 3,5-bis(2-hydroxyethyl)-1,3,5-thiadiazinane-2-thione against Scopolamine-Induced Alzheimer’s Disease
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25169104 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Shagufta und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, University of Peshawar, Peshawar 25120, Pakistan. Hauptthemen laut MEDLINE: Alzheimer Disease, Scopolamine, Thiadiazines, Maze Learning. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Demenz
Abstract (Originalsprache)
Alzheimer’s disease (AD) is the most common neurodegenerative disorder, marked by cognitive impairment. Currently, the available treatment provides only symptomatic relief and there is a great need to design and formulate new drugs to stabilize AD. In the search for a new anti-Alzheimer’s drug, 3,5-bis(2-hydroxyethyl)-1,3,5-thiadiazinane-2-thione (THTT), a tetrahydro-2H-1,3,5-thiadiazine-2-thione derivative, was investigated against a scopolamine-induced Alzheimer’s model. The selected test compound was administered intraperitoneally in three doses (15 mg/kg, 30 mg/kg, and 45 mg/kg). The test compound exhibited an IC50 value of 69.41 µg/mL, indicating its ability to inhibit the acetylcholinesterase enzyme. An antioxidant DPPH assay revealed that the IC50 value of the test compound was 97.75 µg/mL, which shows that the test compound possesses antioxidant activity. The results of behavior tests including the Y-maze and elevated plus maze (EPM) show that the test compound improved short-term memory and spatial memory, respectively. Furthermore, in the Morris water maze (MWM) and light/dark model, the test compound shows improvements in learning and memory. Moreover, the results of histological studies show that the test compound can protect the brain against the harmful effects of scopolamine. Overall, the findings of our investigation suggest that our chosen test compound has disease-modifying and neuroprotective activities against the scopolamine-induced Alzheimer’s model. The test compound may be beneficial, subject to further elaborate investigation for anti-amyloid disease-modifying properties in AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, University of Peshawar, Peshawar 25120, Pakistan.
- DHQ Teaching Hospital Timergara, Lower Dir, Khyber Pakhtunkhwa (KPK), Timergara 18300, Pakistan.
- Department of Pharmacy, Sarhad University of Science and Information Technology, Peshawar 25000, Pakistan.
- Department of Pharmacy, CECOS University of IT and Emerging Sciences, Peshawar 25000, Pakistan.
- Institute of Chemical Sciences, University of Peshawar, Peshawar 25120, Pakistan.
- Institute of Pathology and Diagnostic Medicine, Khyber Medical University Peshawar, Khyber Pakhtunkhwa (KPK), Peshawar 25100, Pakistan.
ORCID-Profile: Gowhar Ali, Adnan Khan, Muhammad Shahid
Zitieren
APA
Shagufta, Ali, G., Khan, A., Rasheed, A., Deeba, F., Ullah, R., Shahid, M., Ali, H., Khan, R., Shamezai, N., & Sharif, N. (2024). Evaluation of the Ameliorative Potential of 3,5-bis(2-hydroxyethyl)-1,3,5-thiadiazinane-2-thione against Scopolamine-Induced Alzheimer’s Disease. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25169104
Vancouver
Shagufta, Ali G, Khan A, Rasheed A, Deeba F, Ullah R, et al. Evaluation of the Ameliorative Potential of 3,5-bis(2-hydroxyethyl)-1,3,5-thiadiazinane-2-thione against Scopolamine-Induced Alzheimer’s Disease. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25169104
BibTeX
@article{Shagufta2024,
author = {Shagufta and Ali, Gowhar and Khan, Adnan and Rasheed, Abdur and Deeba, Farah and Ullah, Rahim and Shahid, Muhammad and Ali, Haleema and Khan, Rasool and Shamezai, Najeebullah and Sharif, Naveed},
title = {Evaluation of the Ameliorative Potential of 3,5-bis(2-hydroxyethyl)-1,3,5-thiadiazinane-2-thione against Scopolamine-Induced Alzheimer’s Disease},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25169104}
}
EUVIMED